R&D News | pharmaphorum

News

Lilly says tirzepatide staves off diabetes in phase 3 trial

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob

News

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

Danish biotech Adcendo has accelerated its progression to a clinical-stage biotech by licensing an antibody-drug conjugate (ADC) from China's Multitude Therapeutics with potential in variou

News

Buoyed by muscular dystrophy data, Avidity raises $345m

Just a few weeks after Avidity Biosciences made a stir with new data on its experimental therapy for Duchenne muscular dystrophy, the biotech has closed a public offering that raised an imp

News

GSK bags breakthrough status for B7-H3 ADC for lung cancer

An antibody-drug conjugate (ADC) that GSK licensed from China's Hansoh Pharma in a $1.7 billion deal last year has been given breakthrough status by the FDA.

News

US govt taps Walgreens for decentralised trials

Retail pharmacy giant Walgreens has signed a five-year contract with the US government – worth up to $100 million – for access to its decentralised clinical trials (DCT) network.

News

Pfizer and BioNTech's COVID/flu vaccine hits a hurdle

Pfizer and BioNTech have been among the leaders in the race to bring a combined COVID-19 and influenza vaccine to market, but have stumbled in the final straight.

Lilly says tirzepatide staves off diabetes in phase 3 trial

Adcendo licenses Multitude anti-TF ADC in $1bn+ deal

Buoyed by muscular dystrophy data, Avidity raises $345m

GSK bags breakthrough status for B7-H3 ADC for lung cancer

US govt taps Walgreens for decentralised trials

Pfizer and BioNTech's COVID/flu vaccine hits a hurdle

FDA hands another rejection to Replimune's melanoma therapy

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks